Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Kromek ‘confident’ for 2017 as losses narrow in first half

“We have entered the second half with significant visibility over revenue in excess of 85% of full year market expectations”
x ray image in airport
Kromek designs develops and produces x-ray and gamma ray imaging and radiation detection products

Radiation detection specialist Kromek Group PLC (LON:KMK) is on track to hit expectations for its current financial year, telling investors it is heading into the second half with excellent visibility over its revenues.

The company said it is looking “to the future with confidence” as it continues to make good progress on the delivery of US$35.5mln of new orders won over the past 18 months.

On top of those contracts already secured, Kromek expects its medical imaging and nuclear detection protection products to be in high-demand over the coming months.

“We have entered the second half with significant visibility over revenue in excess of 85% of full year market expectations,” said chief executive Arnab Basu.

“Overall, our products continue to gain commercial traction resulting from the increasing adoption of cadmium zinc telluride-based technology.”

The ‘confident’ outlook came as Kromek posted a solid set of interim results that continue to demonstrate the improvements being made within the company.

The loss before tax for the six months to October was almost halved to £1.8mln (H1 2016: £3mln), on revenues of £3.8mln – a 19% increase on last year’s number.

Pleasingly for Kromek, product sales accounted for almost three-quarters of those revenues as several research and development programmes moved into the commercialisation phase.

The County Durham-based firm also kept a tight rein on its costs as it managed to shave almost £1mln from its administration expenses.

Underlying losses fell sharply too, down to just £0.7mln compared to £2.3mln a year earlier, while the gross margin remained steady at 53% (H1 2016: 53%).

Kromek still has a decent amount of cash at its disposal as well, with £3.8mln in the bank as of October 31.

“We are pleased to report another period of strong operational progress, continuing the momentum from the previous year as we executed on the significant contracts won in all of our three markets of medical imaging, nuclear detection and security screening,” Basu said.

“We saw high growth in the number of products sold compared with the same period last year and, equally important, a number of R&D programmes have moved into full commercialisation phase.”

View full KMK profile View Profile

Kromek Group PLC Timeline

Related Articles

Initial public offering
June 26 2018
The timing and ability of the group to realise its investments in partner companies is subject to inherent uncertainty due to numerous factors. The company is looking to change its business model a bit to become a financial supporter of companies looking to float or execute a trade sale
The Internet of Things
April 30 2018
Richard Kilsby, the non-executive chairman of Telit, said that the early signs of changes made, especially to the group's activities and cost base, have led to positive operational progress since the beginning of 2018
Picture of XTEK's products
May 04 2018
Patersons' price target of $1.15 implies upside of 130% relative to XTEK's current share price.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use